introduction early detection cancer significantly improve survival offering effective treatment option screening primary method early detection leading decline mortality rate multiple cancer type cervical colorectal lung breast cancer since introduction screening program established screening program continuously investigated evaluated optimize outcome term effectiveness efficiency safety randomized trial cost-effectiveness analysis instrumental evaluating effectiveness screening strategy considering factor target population screening frequency screening initiation age advance medical technology imaging technology liquid biopsy artificial intelligence contribute development accurate invasive cost-effective screening test however quantitative benchmark available directly answer specific counterfactual question patient diagnosed stage cancer age diagnosed months/years earlier would mortality benefit counterfactual analysis provides critical insight causal structure intervention screening program interact study objective provide quantitative benchmark early cancer detection analyzing aforementioned counterfactual question pancreatic ductal adenocarcinoma pdac recent research shown promising stride early detection utilizing deep learning analyze real-world longitudinal disease trajectory datasets method demonstrated impressive ability predict diagnosis year advance quantitative benchmark may provide guidance inform target timeline optimize benefit early detection future pdac intervention unlike prevalent cancer type u.s. colorectal prostate breast lung cancer pdac characterized exceptionally high mortality rate dismal 5-year survival rate 3–10 primarily due late-stage diagnosis aggressive nature malignant tumor ongoing improvement survival rate lung breast cancer suggest pdac could become second leading cause cancer-related death contrast many cancer wide array treatment option including surgery radiation therapy chemotherapy immunotherapy viable method achieving long-term survival pdac patient currently surgery conjunction perioperative chemotherapy additionally natural progression pdac including duration progression remains unclear due absence well-established population screening program part relatively low prevalence lack effective screening tool demonstrably reduce mortality pdac general population accordance study objective developed natural history model pdac simulates cancer incidence mortality data incorporating cancer sojourn time age stage diagnosis estimating cancer sojourn time duration onset detectable preclinical disease clinical diagnosis crucial developing effective screening program optimizing early detection benefit however direct observation sojourn time feasible since disease onset observable investigate sojourn time pdac study primarily relied modeling instance luebeck employed multistage-clonal-expansion msce mathematical model illustrate tumor growth progression dynamic estimating pdac sojourn time year another study estimated pdac sojourn time comparing glycemic profile patient without cancer assuming duration hyperglycemia correlate time tumor present case–control study researcher found patient experienced hyperglycemia average 30–36 month pdac diagnosis however estimate involve substantial uncertainty instance breast cancer well-established screening approach reported sojourn time estimate vary widely ranging two many 7.5 year given uncertainty conducted counterfactual analysis using three different mean sojourn time year incorporated natural history pdac quantified benefit early detection subgroup level e.g. individual-level age-groups whole-group level i.e. aggregated result result modeling simulation overview constructed natural history model pdac consisting four preclinical screen-detectable phase progress clinical staging ultimately result cancer death shown fig assumed preclinical stage detectable screening designed stage follow defined cancer sojourn time meanwhile clinical stage subjected age-dependent cause-specific mortality rate surveillance epidemiology end result seer account treatment therapy available data collection timeframe based design hypothesized earlier cancer detection possibly hypothetical screening intervention would reduce mortality evaluated counterfactual analysis figure study design counterfactual analysis natural history model pdac pancreatic ductal adenocarcinoma undetected state represent preclinical screen-detectable stage detected state represent either clinically detected stage example symptom real-world scenario screen detected stage counterfactual world scenario arrow used indicate possible transition one state another ut1 undetected stage ut2 undetected stage ut3 undetected stage ut4 undetected stage dt1 detected stage dt2 detected stage dt3 detected stage dt4 detected stage counterfactual analysis using microsimulation primary outcome average year gained randomness inherent microsimulation counterfactual analysis influence sensitivity result comparison real-world scenario hypothetical counterfactual world scenario real-world scenario patient clinically diagnosed stage cancer age counterfactual world scenario illustrates could happened patient detected month earlier potentially leading estimated additional life-years full size image model transition probability determined either directly using seer data e.g. age-dependent cancer-specific mortality stage fig calibrating model age-dependent seer pdac incidence stage fig overall mortality rate fig see method detail ran microsimulation model million individual conducted counterfactual analysis cohort patient died pdac comparing counterfactual analysis result corresponding real-world scenario primary outcome average life-years gained fig illustrated fig real-world scenario refers actual observed patient course informed natural history pdac model counterfactual scenario refers hypothetical situation representing might happened intervention characteristic natural history pdac estimated sojourn time model using mean first passage time mfpt markov chain based transition probability see method systematic calibration process able sequentially lower mean sojourn time low month achieving model fit target seer data fig fig investigate variation early detection benefit across different sojourn time performed counterfactual analysis three version model mean sojourn time month refer sj36m sj60m sj120m respectively resulting sojourn time measured based mfpt model displayed increasing trend age fig simple verification evaluated sojourn time distribution selected cohort i.e. patient died pdac found resulting median value month close targeted mean sojourn time fig histogram fig display proportion patient specific sojourn time solid line represent density distribution sojourn time model example within 36-month sojourn time model sj36m distribution sojourn time span brief month extended month median month therefore model capture variability heterogeneity sojourn time among different individual also examined duration preclinical stage selected cohort finding median duration year preclinical stage fig figure characteristic natural history pdac calibration process incorporating sojourn time natural history model pdac strategy sequentially lowering mean sojourn time generated multiple model different mean sojourn time selected three model represent pdac natural history mean sojourn time month month month analysis model referred sj36m sj60m sj120m respectively mean sojourn time defined average value age noticeable increase sojourn time age depicted age-dependent sojourn time trendlines model using dotted line sojourn time distribution selected cohort i.e. individual died pancreatic adenocarcinoma pdac model used counterfactual analysis median value histogram month distribution duration preclinical stage selected cohort sj36m model median duration preclinical stage iii month respectively full size image counterfactual analysis three models—sj36m sj60m sj120m three model version approximately 10,000 people died pdac simulated population million patient model representing lifetime risk dying disease risk marginally lower real-world statistic 1.7 group 10,000 patient constituted cohort used counterfactual analysis model however conduct counterfactual analysis patient health state month earlier original diagnosis e.g. clinical diagnosis based symptomatic presentation patient must one preclinical state specific time point counterfactual scenario convert preclinical undetected state month earlier screen detected state fig ass potential benefit reduced mortality consequently number eligible patient counterfactual analysis depends individual health state time hypothetical screening intervention instance patient health state normal month clinical diagnosis patient must excluded counterfactual analysis accordingly turned back clock time clinical diagnosis e.g. …120 month clinical diagnosis number selected cohort model performing counterfactual analysis continually decreased sigmoidally fig probability staying alive extended duration decrease observed significant drop number selected cohort model shorter sojourn time e.g. eligible counterfactual analysis sj120m sj60m sj30m respectively month prior clinical diagnosis see fig smaller sample size led wider confidence interval analysis result whole-group analysis early detection benefit measured life-years gained whole-group analysis demonstrated early detection beneficial cancer case shorter sojourn time fig sj36m model maximum benefit i.e. average life-years gained achieved cancer detected 4–6 year prior clinical diagnosis resulting average 2.4 life-years gained significantly greater sj60m sj120m model i.e. 2.3 2.1 life-years gained respectively table however maximum benefit sj36m model significantly decreased 2.1 life-years gained earlier intervention whereas maximum benefit sj60m sj120m model remained relatively stable figure simulation outcome benefit early detection estimated average life-years gained pdac natural history model incorporated mean sojourn time month month month i.e. sj36m sj60m sj120m average value represented solid line confidence interval represented shaded region benefit early detection estimated average survival length account lead time bias sj36m model demonstrates significantly greater 0.05 benefit month earlier intervention compared model longer mean sojourn time indicated asterisk full size image table simulation result life-years gained early detection full size table early detection benefit measured survival duration examine impact lead time early detection benefit measured survival duration incorporates lead time time screening diagnosis death fig contrast benefit measured life-years gained displayed distinct pattern based sojourn time benefit measured survival duration exhibited consistent sigmoidal pattern increasing benefit across model regardless sojourn time example assessing benefit survival duration greater benefit shorter sojourn time began intervention month diagnosis persisted month diagnosis however measuring benefit life-years gained model shorter sojourn time showed significantly greater benefit 0.05 compared model longer sojourn time starting intervention month continuing month diagnosis furthermore intriguing phenomenon observed life-years gained—where maximum benefit reached intervention 4–6 year prior diagnosis declined sj36m model maintained sj60m sj120m models—was seen measuring early detection benefit survival duration three model displayed consistent sigmoid-shaped pattern increasing benefit subgroup analysis age-stratified analysis evaluated average life-years gained age group found younger individual experienced greater benefit fig compared older age group younger age group increased uncertainty due relative rarity pdac younger individual figure early detection benefit quantified subgroup age-stratified analysis 36- 60- 120-month sojourn time model individual-level analysis based cancer stage age time diagnosis full size image individual patient level-analysis based simulation result population million patient estimate potential benefit early cancer detection according patient cancer stage age diagnosis example analysis suggests early detection achieved 54-year-old patient diagnosed stage iii cancer likely gain life-years 67-year-old patient diagnosed stage cancer fig however prediction earlier stage younger patient may certain due smaller sample size discussion present quantitative measure potential benefit pdac early detection using counterfactual analysis analysis employed microsimulation model incorporated various sojourn time calibrated robust pdac incidence mortality survival data national cancer institute seer database systematic calibration approach demonstrated capacity determine model age-dependent transition probability set adequately reproduced seer data representing broad range mean sojourn time enabling investigation early detection benefit highly variable sojourn timeframes examined result whole-group-level subgroup-level comprehensively analyze sojourn time impact pdac early detection benefit although sojourn time pdac thought short vary significantly among individual cancer type due factor age genetics lifestyle biological difference immune system response model effectively address individual variability demonstrated fig distribution sojourn time example cohort 36-month sojourn time model sj36m range low month maximum month fig black histogram median value month 1-month sojourn time occurs patient clinically detected stage dt1 residing undetected stage ut1 state month rare indeed scenario account 0.2 simulation result counterfactual analysis discerned clear pattern early detection benefit appeared contingent mean sojourn time pdac three sojourn time model sj36m sj60m sj120m early detection benefit increased intervention 4–6 year prior diagnosis however maximum benefit significantly dropped 0.05 afterward sj36m model relatively maintained longer sojourn time model sj60m sj120m model fig found decline benefit sj36m model maximum benefit reached due characteristic selected cohort instance could perform counterfactual analysis month earlier intervention cohort month undetected period fig median age cancer death cohort sj36m model shifted older age intervention occurred earlier remained relatively constant cohort sj60m sj120m model fig specifically median age cancer death three model intervention close diagnosis e.g. intervention 3-months prior diagnosis early however cohort tested advance e.g. intervention month prior diagnosis median age cancer death sj36 model nearly year old sj60m sj120m model early mid-70s respectively age increase probability benefiting intervention gaining additional life-years decrease analysis also emphasizes significance addressing lead time bias cancer screening early detection study lead time refers interval disease detection screening point would clinically diagnosed via symptom illustrated fig assessed early detection benefit calculating life-years gained doe include lead time however practice early detection benefit often measured survival duration point diagnosis may incorporate lead time determining lead time challenging symptomatic presentation disease vary significantly among individual lead time involved patient may appear live longer reality life extended leading overestimation screening program efficacy phenomenon known lead time bias must considered evaluating impact screening program survival indeed assessed early detection benefit using survival duration instead life-years gained pattern observed based life-years gained longer apparent early detection benefit quantified life-years gained displayed notable difference trend across sojourn time model along various intervention month fig quantified survival duration exhibited consistent sigmoid-shaped pattern increasing benefit across three model fig discrepancy highlight influence lead time evaluating screening program analysis serve benchmark assessing extent lead time bias involved evaluating potential pdac screening program future model-based approach enhance understanding complex problem like tumor dynamic may oversimplify issue numerous assumption challenging include aspect problem mathematical modeling pdac natural history span cellular level e.g. cell growth division death population level e.g. cancer epidemiology including incidence prevalence mortality rate however natural disease course pdac remains elusive model streamlined compared multifaceted pdac model presented koopmann al. incorporates preinvasive preclinical clinical stage various model assumption accurately reflects best available data despite primary focus replicating seer data model naturally generates mean duration preclinical stage weibull distribution shape fig consistent one assumption incorporated koopmann pdac model sojourn time obtained calibration seer data exhibit increasing trend age fig aligning literature suggesting slower cancer progression later age analysis also limited reliance observed data designed clinical stage pdac model subjected age-dependent cause-specific mortality rate seer aiming evaluate mortality benefit earlier detection cause-specific mortality rate seer adjust access impact modern treatment available data collection period therefore assumed earlier intervention would produce mortality benefit counterfactual scenario however important note seer data updated real-time resulting potential lag availability new treatment reflection mortality rate additionally seer data may capture every nuance related treatment access regional difference healthcare system insurance coverage social determinant health could impact access modern treatment lack validation using external data source another limitation however largely available real-world data pdac screening focus high-risk patient seen study cancer pancreas screening-5 caps5 study contrast simulation model explores hypothetical screening general population following natural progression pdac therefore directly comparing result existing real-world data challenging due discrepancy target population provide context model detected approximately case stage meanwhile caps5 study—which focused individual familial genetic risks—reported detection stage underscore potential significant increase early-stage detection screening target high-risk population additionally cap study showed median overall survival 9.8 year screen-detected pdac patient model reflected survival rate detection happened year clinical diagnosis—this timeframe yielded substantial benefit finding perform comprehensive cost-effectiveness analysis study currently screening recommendation pdac primary objective provide quantitative benchmark early detection using counterfactual analysis complete cost-effectiveness analysis would need consider potential harm related early diagnosis quality detriment complication could lead death morbidity estimation medical resource utilization health cost associated early detection effort current study simulation model assumes perfect sensitivity screening choice made explore specific scenario estimating life year could gained pdac patient diagnosed later stage detected earlier current model focus aspect lay strong foundation future cost-effectiveness analysis subsequent study intend ass variety screening strategy different sensitivity specificity evaluate treatment approach tailored cancer stage e.g. based tumor size consider variability sojourn time summary developed microsimulation model incorporated age-varying sojourn time natural history pdac model performed counterfactual analysis provide benchmark early detection measured life-years gained data serve valuable tool assessing overall effectiveness screening program modality early detection pdac additionally method potential applicable type cancer possibly chronic disease preclinical state could benefit early detection material method study design constructed patient-level microsimulation model state transition perform counterfactual analysis cohort patient died pdac within model every individual started normal health state initial age followed age death simulated million individual total monthly cycle individual either remained health state transitioned new health state based predetermined probability derived published data source model calibration process model consisted four preclinical screen-detectable stage ut1 ut2 ut3 ut4 fig progressed clinically detected stage dt1 dt2 dt3 dt4 fig ultimately leading cancer death illustrated fig possible state transition model normal ut1 ut1 ut2 ut2 ut3 ut3 ut4 ut1 dt1 ut2 dt2 ut3 dt3 ut4 dt4 shown fig transition cancer death could occur clinically detected stage dt1 dt2 dt3 dt4 model calibration transition probability calibrated model estimated transition probability age bracket using population-based markov model determined sojourn time utilizing transition probability leveraging markov chain mean first passage time mfpt methodology followed mfpt formula shown =1+ k\ne average number step take end state given current state applied transition probability determined population-based markov model microsimulation approach individual transition state determined based probability also incorporate degree randomness ensuring model doe rigidly adhere fixed sojourn time instead approach reflects probabilistic representation sojourn time transition probability detected stage i.e. dt1 dt2 dt3 dt4 fig cancer death all-cause mortality directly obtained estimate cause-specific survival data pdac provided seer u.s. life table center disease control prevention cdc respectively remaining transition probability obtained estimate calibrating model outcome pdac incidence stage overall mortality seer data sequentially lowering mean sojourn time sojourn time model defined time take individual transition undetected state detected state cancer stage due large parameter space possible age-specific transition probability model lack identifiability using seer data alone calibration target identifiability model validity improved addition sojourn time estimate literature according literature sojourn time pdac estimated year calibrated model using data seer overall mortality incidence stage without including sojourn time calibration target transition probability resulting model give estimate sojourn time month based mfpt formula fig much longer literature estimate pdac model align seer data lengthy sojourn time biologically implausible stemming low transition probability underscore necessity grounding model realistic sojourn time estimate literature enhance identifiability ensure valid representation reach sojourn time year needed sequential process lowering sojourn time strategy calibrate model multiple calibration target detailed step shown note age-dependent pdac mortality rate stage directly used fixed transition probability detected stage e.g. dt1 dt2 dt3 dt4 cancer death mean transition probability change throughout calibration process step preparation target data extracted seer incidence data stage individual age inherently contains noise mitigate risk overfitting due noise generated trendlines stage providing robust target dataset analysis seer data incidence unknown pdac account considerable amount incorporated model distributing stage iii case proportionally incidence age step age-invariant calibration performed stepwise simulated annealing process using age-invariant transition probability i.e. generating single value transition probability vary age refine approximation performing age-variant calibration step step excluded sojourn time calibration target step age-variant calibration starting transition probability obtained step performed stepwise simulated annealing process using age-variant transition probability i.e. generating transition probability vary age satisfactory fit visually confirmed demonstrated fig step excluded sojourn time calibration target step age-variant calibration iteration included mean sojourn time calibration target addition seer incidence mortality performed stepwise simulated annealing process using age-variant transition probability iteration step sequential calibration process repeated step step alternatively achieved target mean sojourn time month result generated multiple model different mean sojourn time fig selected three model representing pdac natural history mean sojourn time month month month analysis model referred sj36m sj60m sj120m respectively counterfactual simulation determine earlier diagnosis pdac lead mortality benefit e.g. life-years gained performed counterfactual analysis using microsimulation model sj36m sj60m sj120m comparing result counterfactual scenario real world measured average life-years gained proportion patient involved lead time bias i.e. case life-years gained month screening intervention primary outcome fig real-world scenario refers actual situation following natural history pdac model counterfactual scenario refers hypothetical situation representing might happened early intervention illustrated fig tested screening intervention month earlier simulated million individual starting age normal health state tracked monthly health transition age death identified individual died pdac simulation recorded age month diagnosis perform counterfactual analysis detected patient pdac earlier tracked back individual health state history month clinical diagnosis e.g. symptomatic diagnosis health state month diagnosis one undetected state changed corresponding detected state normal excluded patient counterfactual analysis thus selected cohort eligible counterfactual analysis month screening intervention one specific example implementing counterfactual analysis patient diagnosed detected stage dt4 model month diagnosis patient undetected stage iii ut3 changed state ut3 detected stage iii dt3 meant patient screen detected month continued simulation age ensuring patient remained alive model time would died pdac real-world scenario approach excluded rare instance patient might die earlier counterfactual scenario real-world either due all-cause mortality e.g. heart attack car accident etc cancer potentially resulting negative effect overall well-being caused knowing cancer diagnosis earlier life-years gained survival duration using counterfactual result assessed early detection benefit measuring life-years gained survival duration life-years gained represents additional year life individual experience counterfactual world compared real-world survival duration measure time screening intervention death counterfactual world individual die either pdac all-cause mortality counterfactual world whole-group subgroup analysis month screening intervention selected cohort eligible counterfactual analysis calculated life-years gained individual comparing outcome counterfactual scenario real world whole-group analysis presented average life-years gained selected cohort month screening intervention model sj36m sj60m sj120m subgroup analysis collected result individual belonging specific stage age age group interest evaluated average life-years gained since model run monthly cycle patient age represented year month example want ass potential benefit early detection patient diagnosed pdac stage iii age collect result individual diagnosed pdac stage iii age ranging year month year month model sensitivity two part inherent randomness microsimulation model involved analytical process marked red asterisk fig due relatively low incidence rate pdac microsimulation model insufficient number individual result greater degree uncertainty result therefore simulated million individual resulted successful alignment target data fig counterfactual analysis performed iteration case presented mean value confidence interval statistic performed independent sample -test comparing mean two group one-way anova comparing mean three group significance level 0.05